FDA Grants Novel Liquid Biopsy Assay Breakthrough Device Designation to...
The FDA has granted breakthrough device designation to the novel, microbiome-driven, liquid biopsy assay OncobiotaLUNG for the detection of lung carcinomas, according to a press release from developer...
View ArticleMicronoma Breaks Through With Microbiome-BIOTECH: FDA Designation a ‘Milestone’
Micronoma’s microbiome platform is breaking into its next phase with validation from the U.S. Food and Drug Administration. Last month, the San Diego-based company announced that the FDA has given its...
View ArticleFrost & Sullivan Lauds Micronoma with Award for Technology Innovation Leadership
Analysts credit the Oncobiota microbiome-driven liquid biopsy platform for identifyingthe “infinite potential” of using microbiome markers to diagnose cancer.March 29, 2023. SAN DIEGO, Calif.–Based on...
View ArticleIncidental Detection of Lung Cancer: Can We Be More Proactive?
Up to two million incidentally detected pulmonary nodules (IPN) appear each year onimages coming from diagnostic scans that patients undergo for reasons unrelated tolung cancer. These nodules are...
View ArticleTeam Spotlight: Nick Grigoriev, Customer Care Manager
Nick started working for Micronoma in February 2023. He was born and raised in San Diego, and went to college at UC Davis. As a Customer Care Manager, Nick’s main goal is to create a white glove...
View ArticleMicronoma Presents State-of-the-Art Metagenomic Liquid Biopsy
AACR 2023 presentation highlights noteworthy diagnostic performance potential using cell-free microbial DNA in diagnosing early-stage lung cancer April 19, 2023. San Diego, CA—Highlighting that...
View ArticleMicronoma Teams Up with NYU Grossman School of Medicine on Lung Cancer...
This latest collaboration seeks synergistic methodologies that will enable the earliest, best predictions of lung cancer May 18, 2023. SAN DIEGO, Calif.– Micronoma announced today that it is serving...
View ArticleTeam Spotlight: Jerry Lee, Senior Scientist- Bioinformatician
Jerry started working for Micronoma in May 2023. He was born in China, and raised in San Francisco, where he also went to college (California State, East Bay). As a Senior Scientist, Jerry is part of...
View ArticleClik here to view.
The Power of Microbiome Integration to Multiomics in Early Cancer Detection:...
The OncobiotaLUNGdetect is a multi-species, multi-omic liquid biopsy assay that will aid clinicians in risk stratification of pulmonary nodules. Micronoma is the first company to commercialize an...
View ArticleDrawing the Best Results from Blood Biopsies
We’ve come a long way since tissue biopsies were considered the go-to way to obtain samples needed to test for cancer. Breast cancer, prostate cancer, and lung cancer all required invasive methods to...
View Article